2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Workforce, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Paroxysmal Nocturnal Hemoglobinuria, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Metabolic Disorders, Iron Deficiency, Iron Overload, B Cell Lymphoma, Research, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4388 Cost-effectiveness of marstacimab prophylaxis versus factor prophylaxis in adult previously treated patients (PTPs) with severe hemophilia A without inhibitors in the United States

Sam Hirniak, PhD, Kristina Rinaldi2, Satoko Ito, MD, PhD3, Manraj Sra, MD4, Ding Quan Ng, PhD5, Robert Bona, MD6, Ming Lim, MBBCh, MS7, Adam Cuker, MD, MS8, George Goshua, MD, SM9
1 Yale Cancer Center & Yale School of Medicine, New Haven, United States
2 Yale Cancer Center & Yale School of Medicine, New Haven, United States
3 Yale Cancer Center & Yale School of Medicine, New Haven, United States
4 Yale Cancer Center & Yale School of Medicine, New Haven, United States
5 Yale Cancer Center & Yale School of Medicine, New Haven, United States
6 Yale Cancer Center & Yale School of Medicine, New Haven, United States
7 University of Utah, Salt Lake City, United States
8 University of Pennsylvania, Philadelphia, United States
9 Yale Cancer Center & Yale School of Medicine, New Haven, United States

Introduction: Prophylaxis for people living with severe hemophilia A (HA) in high-income countries is transitioning from factor to non-factor substitutes. Prophylaxis with factor products is expensive, introduces inhibitor formation risk and requires frequent intravenous infusions, impeding the achievement of a hemophilia-free mind. Marstacimab, a once-weekly subcutaneous monoclonal non-factor substitute targets tissue factor pathway inhibitor, demonstrated superior bleed prevention versus factor prophylaxis in the phase 3 BASIS program, leading to FDA approval for adults and children with severe HA. The cost-effectiveness of marstacimab prophylaxis in hemophilia care is unknown. We sought to fill this gap with the first cost-effectiveness analysis of marstacimab versus factor prophylaxis for people living with severe HA.

Methods: In this independent economic evaluation, we developed a Markov cohort to evaluate the cost-effectiveness of marstacimab versus either standard half-life (SHL) or extended half-life (EHL) factor VIII prophylaxis in PTPs with severe HA without inhibitors. Clinical efficacy inputs were informed from the non-inhibitor HA-specific cohort of the phase 3 BASIS trial of adult patients with severe HA (median age 30). The base-case examined SHL prophylaxis at 87.5 IU/kg weekly dosing, with EHL prophylaxis evaluation in scenario analysis. Costs were sourced from the largest health insurer in the United States (US), Centers for Medicare & Medicaid Services, and supplemented with chronic arthropathy and post intracranial hemorrhage utilization literature. Health-related quality of life was expressed in quality-adjusted life years (QALYs) and quantified with age-dependent hemophilia-specific utilities accounting for target joint prevalence, with an additional scenario analysis evaluating BASIS trial-specific health utilities. We internally validated our model against BASIS trial results for both annual bleeding events and annual FVIII consumption. We conducted our analyses from a US health system perspective across all accepted US willingness-to-pay (WTP) thresholds. The primary outcome was the incremental cost-effectiveness ratio (ICER) or, if a therapy was cost-saving, its reformulation the incremental net monetary benefit (iNMB). We concluded with sensitivity analyses to assess the influence of individual model parameters on model results and to quantify uncertainty in all parameters simultaneously over 10,000 Monte Carlo simulations.

Results: For validation, the projected model-based annualized bleed rate (ABR) difference was 4.07 (BASIS: 3.96), with mean annualized per-person breakthrough bleed SHL-specific factor consumption of 130 and 296 IU/kg for marstacimab and factor prophylaxis arms (BASIS: 127 and 306 IU/kg), respectively. Marstacimab and SHL prophylaxis accrued 19.26 and 15.10 discounted QALYs at discounted costs of $20.0 and $ 16.9 million, respectively, with an ICER of $0.7 million/QALY (95% CI: $0.6-1.1 million/QALY). Threshold analysis showed that marstacimab would be cost-effective above weekly SHL dosing of >102 IU/kg. In scenario analysis using BASIS trial-specific utilities, marstacimab and SHL prophylaxis accrued 19.64 and 18.71 QALYs, resulting in an ICER of $3.2 million/QALY (95% CI: $1.6-7.5 million/QALY), with a weekly SHL dosing threshold of >104 IU/kg. In scenario analysis with EHL, marstacimab prophylaxis provided more discounted QALYs (19.26 vs 15.97) at lower discounted lifetime costs ($20.0 million vs $25.3 million), with an iNMB of $5.7 million in favor of marstacimab (95% CI: $5.1-6.1 million) at a WTP of $120,000 per QALY. Deterministic sensitivity analyses showed that therapeutic price, prophylactic FVIII dose, and patient body weight had the greatest impact on the ICER. Specifically, marstacimab could be cost-effective when patient body weight exceeds 116% of age-dependent population median body weight or with a 13% price reduction. Across sets of 10,000 second-order Monte Carlo iterations in probabilistic sensitivity analyses 1) SHL was favored over marstacimab in 100% and 2) marstacimab was favored over EHL in 100%.

Conclusion: Compared with FVIII prophylaxis, marstacimab improved quality-adjusted life expectancy and reduced FVIII consumption for breakthrough bleeding. Marstacimab can be a cost-effective option for patients with high baseline prophylactic SHL FVIII utilization. It is cost-saving versus EHL.

Sam Hirniak, PhD: No relevant conflicts of interest to declare.